Use of perlecan domain V in treating amyloidogenic disease
MetadataShow full item record
The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
Bix, Gregory J.; Wright, Sarah; Griswold-prenner, Irene (2016). Use of perlecan domain V in treating amyloidogenic disease. United States. Patent and Trademark Office; Texas A&M University. Libraries. Available electronically from